Progressive lipodystrophy, a diagnosis at a glance

Nephrology Dialysis Transplantation

Volumn 13, Issue 2, 1998, Pages 507-509

  Smak Gregoor, Peter J H ^a,c   Van Bommel, Eric F H ^b   Ketterings, Cornelius ^a   Van Saase, Jan L C M ^a   Kramer, Pieter ^a  

^a St Clara Hospital   (Netherlands)

^b Drechtsteden Ziekenhuis   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY FAT; CASE REPORT; FEMALE; HUMAN; LIPODYSTROPHY; PRIORITY JOURNAL;

EID: 0031975712     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027859     Document Type: Article

References (26)

1. Senior B, Gellis SS. The syndromes of total lipodystrophy and of partial lipodystrophy. Pediatrics 1964; 33: 593-612
2. Peters DK, Williams DG, Charlesworth JA et al. Mesangiocapillary nephritis, partial lipodystrophy and hypocomplementaemia. Lancet 1973; 2: 535-538
3. Taylor WB, Honeycutt WM. Progressive lipodystrophy and lipoatrophic diabetes. Arch Dermatol 1961; 84: 31-36
4. Poley JR, Stickler GB. Progressive lipodystrophy. Am J Dis Child 1963; 106: 356-363
5. Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med 1972; 163: 343-354
6. Sissons JGP, West RJ, Fallows J et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976; 294: 461-465
7. Williams DG, Charlesworth JA, Lachmann PJ, Peters DK. Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephrits. Lancet 1973; 1: 447-449
8. Davis AE, Ziegler JB, Gelfand EW, Rose EJ, Alper CA. Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci USA 1977; 75: 3980-3983
9. Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): stabilisation of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976; 116: 1-7
10. Daha MR, Austen FK, Fearon DT. Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. J Immunol 1978; 120: 1389-1394
11. Donadio JV. Membranoproliferative glomerulonephritis. In: Schrier RW, Gottschalk CW (eds). Diseases of the Kidney (5 edn). Little Brown, Boston, 1993; 1815-1837
12. Vallota EH, Forristal J, Davis NC, West CD. The C3 nephritic factor and membranoproliferative glomerulonephritis: correlation of serum levels of the nephritic factor with C3 levels, with therapy, and with progression of the disease. J Pediatr 1972; 80: 947-959
13. Finn JE, Mathieson PW. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immunol 1993; 91: 410-414
14. Ohi H, Watanabe S, Fujita T, Yagusi T. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 1992; 89: 479-484
15. Ljunghall S, Fjellström KE, Wibell L. Partial lipodystrophy and chronic hypocomplementemic glomerulonephritis. Acta Med Scand 1974; 195: 493-497
16. Frémeaux-Bacchi V, Weiss L, Brun P, Kazatchkine MD. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol Dial Transplant 1994; 9: 811-814
17. Vallote EH, Forristal J, Spitzer RE, Davis NC, West CD. Continuing C3 breakdown after bilateral nephrectomy in patients with membranoproliferative glomerulonephritis. J Clin Invest 1971; 50; 552-558
18. Frémeaux-Bacchi V, Weiss L, Demouchy C, May A, Palomera S, Kazatchkine MD. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 1994; 9: 1747-1750
19. Spitzer RE, Stitzel AE, Tsokos G. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production. Clin Immunol Immunopathol 1992; 64: 177-183
20. Spitzer RE, Stitzel AE, Tsokos G. Study of the idiotypic response to autoantibody to the alternative pathway C3/C5 convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals. Clin Immunol Immunopathol 1992; 62: 291-294
21. Coleman TH, Farristal J, Osaka T, West CD. Inherited complement component deficiencies in membranoproliferative glomerulonephritis. Kidney Int 1983; 24: 681-690
22. Pickering RJ, Michael AF, Herdman RC, Good RA, Gewurz H. The complement system in chronic glomerulonephritis. Three newly associated aberrations. J Pediatr 1971; 78: 30-43
23. Habib R, Loirat C, Gubler MC et al. Morphology and serum complement levels in membranoproliferative glomerulonephritis. Adv Nephrol 1974; 4: 109-136
24. van Bommel EFH, Ouwehand AJ, Mulder AH, Weimar W. Mesangiocapillary glomerulonephritis associated with hereditary angioedema. Nephron 1995; 69: 178-179
25. Schifferli JA, Ng YC, Peters DK. The role of complement and its receptors in the elimination of immune complexes. N Engl J Med 1986; 24: 315-317
26. Mathieson PW, Wurzner R, Oliviera DB, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993; 177: 1872-1831